Premium
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience
Author(s) -
Traynor Anne M.,
Richards Gregory M.,
Hartig Gregory K.,
Khuntia Deepak,
Cleary James F.,
Wiederholt Peggy A.,
Bentzen Søren M.,
Harari Paul M.
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21224
Subject(s) - medicine , cisplatin , head and neck cancer , radiation therapy , head and neck squamous cell carcinoma , head and neck , chemotherapy , nuclear medicine , cancer , toxicity , stage (stratigraphy) , oncology , urology , surgery , paleontology , biology
Background. We retrospectively examined the treatment efficacy and toxicity profile of intensity‐modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC). Methods. A total of 57 patients with stage III or IV HNSCC were treated with IMRT and concurrent weekly cisplatin (dosed at 30 mg/m 2 ) between November 2001 and May 2007. The median prescription dose to the gross tumor volume was 70 Gy (using 2.0–2.2 Gy daily fractions). Results. In‐field tumor control at 2 years was 89.1%, locoregional control was 85.5%, and overall survival was 86.9%. The median radiation dose delivered was 70 Gy. The mean dose intensity of cisplatin administered was 25.7 mg/m 2 /week. Conclusion. Comprehensive head and neck IMRT to 70 Gy delivered with weekly cisplatin chemotherapy (30 mg/m 2 ) is feasible and generally well tolerated. © 2009 Wiley Periodicals, Inc. Head Neck, 2010